Recently, China’s Central Commission for Discipline Inspection (CCDI) and the National Supervisory Commission have repeatedly highlighted serious problems in the healthcare sector, signaling a significant intensification of anti-corruption efforts. Key areas under scrutiny include pharmaceutical procurement, medical equipment acquisition, and the use of health insurance funds. The CCDI pointed out entrenched issues such as ‘kickback-driven sales,’ inflated pricing, and illicit rebates, which severely harm public interests and distort the industry ecosystem. In response, disciplinary authorities are collaborating with health and medical insurance regulators to strengthen oversight of critical positions and personnel, while also promoting long-term mechanisms—such as improving centralized procurement systems, enhancing transparency, and implementing intelligent monitoring. This campaign not only targets individual violations but emphasizes systemic reform, aiming to eliminate the root causes of corruption and restore integrity within the healthcare system. As enforcement intensifies, the sector is accelerating toward greater compliance and transparency.
近期，中央纪委国家监委多次点名医疗领域存在的突出问题，释放出医疗反腐持续加码的强烈信号。从药品采购、设备引进到医保基金使用，多个环节被列为整治重点。中纪委指出，部分医疗机构存在‘带金销售’、虚高定价、回扣返利等顽疾，严重损害群众利益和行业生态。为此，纪检监察机关正协同卫健、医保等部门，强化对关键岗位、重点人员的监督，并推动建立长效机制，如完善集中采购制度、加强信息公开和智能监管。此次行动不仅聚焦个案查处，更注重系统治理，旨在铲除滋生腐败的土壤，重塑风清气正的医疗环境。随着反腐力度不断加大，医疗行业的合规化、透明化改革正在加速推进。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/12947.html